The absence of this consideration may limit the applicability of the findings in cases where different disease mechanisms are at play between cancer mutations and germline variants (e.g., variants in MYD88, where germline variants can lead to immunodeficiency through loss of function [38,39], but acts as a proto-oncogene in cancer [40]). This evidence concerns the gene MYD88 and immune system disorder.